High Court Won't Review Enbrel Patent Ruling
The U.S. Supreme Court on Monday opted to leave alone a ruling that Amgen Inc.'s patents for its blockbuster autoimmune drug Enbrel weren't invalid for double-patenting, effectively blocking Sandoz Inc. from...To view the full article, register now.
Already a subscriber? Click here to view full article